Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.40 |
| ▸ | FABP7 | O15540 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400520 | 1.00 | KMT2A (0.51) | KMT2AEPHX2OPRD1CASP3FABP5 | |
| SCHEMBL31733654 | 1.00 | KMT2A (0.51) | KMT2AEPHX2OPRD1CASP3FABP5 | |
| SCHEMBL29995975 | 0.95 | KMT2A (0.48) | KMT2AEPHX2OPRD1CASP3FABP5 | |
| SCHEMBL30895521 | 0.95 | KMT2A (0.48) | KMT2AEPHX2OPRD1CASP3FABP5 | |
| SCHEMBL3087950 | 0.88 | KMT2A (0.58) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL29470973 | 0.84 | KMT2A (0.57) | KMT2AEPHX2OPRD1CASP3FABP5 | |
| SCHEMBL12391727 | 0.84 | KMT2A (0.57) | KMT2AEPHX2OPRD1CASP3FABP5 | |
| SCHEMBL7855942 | 0.84 | KMT2A (0.69) | KMT2AEPHX2CASP3 | |
| SCHEMBL17015150 | 0.84 | KMT2A (0.57) | KMT2AEPHX2OPRD1CASP3FABP5 | |
| SCHEMBL30174112 | 0.83 | KMT2A (0.59) | KMT2AEPHX2OPRD1CASP3FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8734870-B2 | Dendrimers and dendrimer applications | NATIONAL UNIVERSITY OF IRELAND, GALWAY (IE) | 2014-05-27 | — | — | US | disclosed |
| US-20110217750-A1 | Dendrimers and Dendrimer Applications | NATIONAL UNIVERSITY OF IRELAND, GALWAY (IE) | 2011-09-08 | — | — | US | disclosed |
| US-7897733-B2 | Rapamycin conjugates and antibodies | PFIZER, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7662782-B2 | Melanocortin 1 receptor selective compounds | ACTION PHARMA A/S (DK) | 2010-02-16 | — | — | US | disclosed |
| WO-2009115580-A2 | DENDRIMERS AND DENDRIMER APPLICATIONS | NATIONAL UNIVERSITY OF IRELAND, GALWAY (IE) | 2009-09-24 | — | — | WO | disclosed |
| EP-1181938-B1 | Rapamycin conjugates and antibodies | WYETH CORP (US) | 2007-11-14 | — | — | EP | disclosed |
| US-7279561-B1 | Anti-rapamycin monoclonal antibodies | WYETH (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279562-B2 | Rapamycin conjugates | WYETH (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070027086-A1 | Melanocortin 1 receptor selective compounds | SZARDENINGS MICHAEL | 2007-02-01 | — | — | US | disclosed |
| EP-1693382-A2 | Melanocortin 1 receptor selective compounds | Action Pharma A/S (DK) | 2006-08-23 | — | — | EP | disclosed |
| US-6271402-B1 | CULTURE PRODUCT OF FUSARIUM SP., MF6381 (ATCC 74469) | MERCK & CO., INC. | 2001-08-07 | — | — | US | disclosed |
| EP-1075492-A1 | MELANOCORTIN 1 RECEPTOR SELECTIVE COMPOUNDS | Wa Pharm AB (SE) | 2001-02-14 | — | — | EP | disclosed |
| EP-1025127-A1 | MSH-RECEPTOR SUBTYPE SELECTIVE CYCLIC PEPTIDES | Wapharm AB (SE) | 2000-08-09 | — | — | EP | disclosed |
| WO-2000036132-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-1999057148-A1 | MELANOCORTIN 1 RECEPTOR SELECTIVE COMPOUNDS | WA PHARM AB (SE) | 1999-11-11 | — | — | WO | disclosed |
| WO-1998037097-A1 | MSH-RECEPTOR SUBTYPE SELECTIVE CYCLIC PEPTIDES | WAPHARM AB (SE) | 1998-08-27 | — | — | WO | disclosed |
| EP-0710110-A4 | RAPAMYCIN CONJUGATES AND ANTIBODIES | ABBOTT LAB (US) | 1997-06-18 | — | — | EP | disclosed |
| EP-0710110-A1 | RAPAMYCIN CONJUGATES AND ANTIBODIES | ABBOTT LABORATORIES (US) | 1996-05-08 | — | — | EP | disclosed |
| WO-1994025072-A1 | RAPAMYCIN CONJUGATES AND ANTIBODIES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-11-10 | — | — | WO | disclosed |
| WO-1994025022-A1 | RAPAMYCIN CONJUGATES AND ANTIBODIES | ABBOTT LABORATORIES (US) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110217750-A1 | Dendrimers and Dendrimer Applications | ADH1A, DNPH1, SAMHD1 | KMT2A 1925/4885EPHX2 313/4885OPRD1 2830/4885 |
| US-20070027086-A1 | Melanocortin 1 receptor selective compounds | MC5R, MC1R, MC2R | KMT2A 2343/4885EPHX2 2996/4885OPRD1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.